39 citations
,
November 2015 in “Pediatric Nephrology” In this study, rituximab treatment for children with steroid-dependent nephrotic syndrome was associated with a longer remission time and fewer side effects compared to cyclophosphamide.
16 citations
,
August 2011 in “Annals of Allergy Asthma & Immunology” This report describes a case of a 19-year-old woman experiencing severe recurrent angioedema with airway issues, leading to multiple emergency visits and unsuccessful treatment with typical steroid-sparing agents.
5 citations
,
June 2001 in “Annals of Internal Medicine” This report describes a case where rituximab provided durable remission in a patient with refractory aggressive diffuse B-cell lymphoma that was unresponsive to prior chemotherapy.
2 citations
,
December 2024 in “International Journal of Rheumatic Diseases” This study describes the first reported case of a 37-year-old woman developing alopecia universalis after switching from rituximab to ocrelizumab for progressive multiple sclerosis, suggesting that ocrelizumab may trigger autoimmune reactions in immunocompromised patients.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy. Discontinuation of rituximab and initiation of oral baricitinib led to improvement in skin conditions, underscoring potential immune-related skin effects from rituximab.
March 2026 in “SHILAP Revista de lepidopterología” In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy, suggesting a rare association between the drug and these immune-mediated skin conditions, highlighting the potential benefit of early intervention with baricitinib.
January 2026 in “Case Reports in Rheumatology” This case report described a woman with systemic lupus erythematosus and Type 2 diabetes who developed dermatomyositis, showing improvements in muscle strength and creatine kinase levels following treatment with rituximab.
April 2020 in “Rheumatology” This case report describes successful and sustained treatment of alopecia universalis with rituximab in a patient also diagnosed with dermatomyositis, suggesting a potential role for B cells in its pathogenesis.
May 2026 in “Indian Journal of Dermatology” This study reports that Rituximab may be a safe and effective treatment for refractory juvenile systemic lupus erythematosus complicated by macrophage activation syndrome, allowing for successful steroid tapering.
June 2024 in “The Journal of Dermatology” This letter to the editor addresses previously published work about risk factors of rituximab-induced thrombocytopenia in autoimmune bullous disease patients but presents no new research findings.
213 citations
,
June 2017 in “Rheumatology” This guideline outlines the management of systemic lupus erythematosus in adults but reports no new clinical findings.
73 citations
,
March 2014 in “Journal of The American Academy of Dermatology” Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.
58 citations
,
April 2012 in “Journal of the American Academy of Dermatology” Graft-versus-host disease is a complication where donor immune cells attack the recipient's body, often affecting the skin, liver, and gastrointestinal tract.
46 citations
,
June 2018 in “American Journal of Clinical Dermatology” This review summarizes the clinical, trichoscopic, and histopathological features of alopecia types associated with cutaneous and systemic lupus erythematosus and explores their links to disease activity, but it reports no new clinical results.
18 citations
,
July 2016 in “Journal of The American Academy of Dermatology” This study reported that both primary and secondary cutaneous follicle center lymphomas can present with atypical scalp or forehead lesions, leading to potential misdiagnosis as other skin conditions.
15 citations
,
January 2014 in “Anais Brasileiros de Dermatologia” This review discusses the varied cutaneous manifestations of Systemic Lupus Erythematosus and outlines treatment approaches, but it reports no new clinical findings.
13 citations
,
March 2011 in “British Journal of Dermatology” This report describes a case of primary cutaneous follicle centre cell lymphoma presenting as hair thinning on the scalp, which is not a recognized feature of the condition.
9 citations
,
January 2018 in “Acta Clinica Croatica” This review suggests that bendamustine, alone or in combination, shows effectiveness in treating indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia, with recent studies highlighting its benefits especially in combination therapies, while balancing efficacy with a favorable toxicity profile.
7 citations
,
September 2021 in “Dermatologic Therapy” This review summarizes treatments for scalp involvement in dermatomyositis and suggests that therapies like low-dose naltrexone and platelet-rich plasma may warrant further investigation, although evidence remains limited.
7 citations
,
October 2015 in “Actas Dermo-Sifiliográficas” This article reviews the increasing incidence of frontal fibrosing alopecia since its first description in 1994 and reports no new results.
6 citations
,
November 2018 in “Case reports in nephrology and dialysis” This case report detailed a 71-year-old male with Cronkhite-Canada syndrome and associated membranous nephropathy, who showed a significant improvement in skin and gastrointestinal symptoms, and remission of nephropathy, after treatment with rituximab, cyclosporine, and azathioprine.
4 citations
,
June 2025 in “Frontiers in Immunology” This review discusses the role of the BAFF system in autoimmune diseases and highlights its therapeutic potential, emphasizing the need for disease-specific clinical trials to improve treatment strategies.
3 citations
,
May 2024 in “International Journal of Dermatology” In this study, pediatric pemphigus was found to have a chronic but mostly benign progression, with initial remission from corticosteroids typically requiring additional immunomodulators for long-term control, and the authors advocate for using rituximab in these cases.
3 citations
,
April 2019 in “Journal of the Endocrine Society” This case report describes a rare instance of Satoyoshi syndrome in a 27-year-old Asian American woman, notable for her normal ovarian function despite typical syndrome features.
3 citations
,
January 2019 in “Skin appendage disorders” This case report describes a patient with primary cutaneous follicle center lymphoma who developed an alopecic atrophic patch potentially due to pressure, following rituximab treatment.
2 citations
,
October 2022 in “Current Allergy and Asthma Reports” This review outlines the various adverse reactions to biologic therapies in Allergy/Immunology, emphasizing the clinical and management challenges due to overlapping reaction phenotypes and the need for more refined diagnostic and management strategies.
2 citations
,
October 2022 in “Current Dermatology Reports” This review discusses the impact of immune-modifying therapies on COVID-19 vaccine responses, noting that a complete vaccine course can improve initially inadequate humoral responses among treated individuals compared to a single dose.
2 citations
,
October 2022 in “British journal of haematology” This study reports the first successful use of zanubrutinib to treat a 15-year-old Chinese girl with severe refractory Evans' syndrome, resulting in a sustained recovery of platelet counts and haemoglobin levels.
2 citations
,
January 2021 in “Case reports in endocrinology” In this case report, a girl with autoimmune polyglandular syndrome type 1 experienced stabilized disease and reversal of alopecia universalis after treatment with glucocorticoids and methotrexate.
1 citations
,
April 2024 in “Clinical Medicine” This case report suggests that Rituximab and high-dose immunosuppressive therapy may be effective for treating severe cutaneous lupus erythematosus like TEN-like ACLE, leading to remission and recovery.